Detalhe da pesquisa
1.
Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer.
Stem Cells
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563224
2.
Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study.
Oncologist
; 29(5): 407-414, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38309720
3.
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.
Curr Opin Oncol
; 36(3): 164-168, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573205
4.
Relugolix in Clinical Practice: The Best Route for All?
Oncologist
; 28(8): 647-650, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37162497
5.
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Oncologist
; 28(4): 364-e217, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640137
6.
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Oncologist
; 28(7): 642-e561, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37134294
7.
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.
Oncologist
; 27(9): 718-e694, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640474
8.
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer.
Oncologist
; 26(9): 729-e1493, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333820
9.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int
; 127(4): 435-444, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969563
10.
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Oncologist
; 25(12): 1013-e1824, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510664
11.
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Oncologist
; 25(6): 479-e899, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31594913
12.
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Oncologist
; 25(7): 560-e1006, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876334
13.
Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate
; 79(3): 244-258, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30381857
14.
Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small.
Oncologist
; 29(3): 185-189, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206818
15.
Natural history and imaging in men with high genetic risk for developing prostate cancer.
Can J Urol
; 26(5 Suppl 2): 7-8, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31629414
16.
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 118(4): 590-7, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26780387
17.
Metabolic syndrome in prostate cancer: impact on risk and outcomes.
Future Oncol
; 12(16): 1947-55, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27067408
18.
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.
BJU Int
; 116(4): 546-55, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25407442
19.
Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
South Med J
; 108(4): 224-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25871992
20.
Increasing diversity in clinical trials: Demographic trends at the national cancer institute, 2005-2020.
J Natl Cancer Inst
; 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38374401